Altimmune announces public offering to fund Phase 3 liver disease trial
Go back to Altimmune announces public offering to fund Phase 3 liver disease trial| iShares Diversified Alternatives Trust (NASDAQ: ALT) | Delayed: 2.97 +0.04 (1.37%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.93 | 52 Week High | $54.24 | |||
| Open | $2.88 | 52 Week Low | $48.35 | |||
| Day High | $3.04 | P/E | N/A | |||
| Day Low | $2.88 | EPS | $0.00 | |||
| Volume | 3,222,135 | |||||
